144 related articles for article (PubMed ID: 35844167)
1. Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer.
Rushworth LK; Loveridge C; Salji M; MacLeod M; Mui E; Sumpton D; Neilson M; Hedley A; Alexander L; McCartney E; Patel R; Wallace J; Delles C; Jones R; Leung HY
BJU Int; 2023 Feb; 131(2):236-243. PubMed ID: 35844167
[TBL] [Abstract][Full Text] [Related]
2. Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer.
Jung J; Lee C; Lee C; Kwon T; You D; Jeong IG; Hong JH; Ahn H; Kim CS
Korean J Urol; 2015 Sep; 56(9):630-6. PubMed ID: 26366275
[TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
4. Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.
Siltari A; Riikonen J; Koskimäki J; Pakarainen T; Ettala O; Boström P; Seikkula H; Kotsar A; Tammela T; Helminen M; Raittinen PV; Lehtimäki T; Fode M; Østergren P; Borre M; Rannikko A; Marttila T; Salonen A; Ronkainen H; Löffeler S; Murtola TJ
BMJ Open; 2022 Apr; 12(4):e050264. PubMed ID: 35487730
[TBL] [Abstract][Full Text] [Related]
5. Statin use and outcomes of oncological treatment for castration-resistant prostate cancer.
Peltomaa AI; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Sci Rep; 2023 Nov; 13(1):18866. PubMed ID: 37914793
[TBL] [Abstract][Full Text] [Related]
6. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
Dambal S; Howard LE; Allott EH; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
J Urol; 2020 Jan; 203(1):120-127. PubMed ID: 31430247
[TBL] [Abstract][Full Text] [Related]
7. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.
Hamilton RJ; Ding K; Crook JM; O'Callaghan CJ; Higano CS; Dearnaley DP; Horwitz EM; Goldenberg SL; Gospodarowicz MK; Klotz L
Eur Urol; 2021 Apr; 79(4):446-452. PubMed ID: 33390282
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
Nadal R; Tsai HL; Sinibaldi VJ; Paller CJ; Antonarakis ES; Denmeade SR; Carducci MA; Eisenberger MA
Prostate; 2016 Apr; 76(5):512-20. PubMed ID: 26689606
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
10. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
11. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
Ji G; Song G; Huang C; He S; Zhou L
Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
13. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.
Di Lorenzo G; Sonpavde G; Pond G; Lucarelli G; Rossetti S; Facchini G; Scagliarini S; Cartenì G; Federico P; Daniele B; Morelli F; Bellelli T; Ferro M; De Placido S; Buonerba C
Eur Urol Focus; 2018 Dec; 4(6):874-879. PubMed ID: 28753882
[TBL] [Abstract][Full Text] [Related]
14. Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study.
Pu YS; Ahn H; Han W; Huang SP; Wu HC; Ma L; Yamada S; Suga K; Xie LP
Adv Ther; 2022 Jun; 39(6):2641-2656. PubMed ID: 35397772
[TBL] [Abstract][Full Text] [Related]
15. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Lohaus F; Zöphel K; Löck S; Wirth M; Kotzerke J; Krause M; Baumann M; Troost EGC; Hölscher T
Eur Urol; 2019 Apr; 75(4):548-551. PubMed ID: 30578119
[TBL] [Abstract][Full Text] [Related]
16. Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer.
Hah YS; Lee JS; Rha KH; Hong SJ; Chung BH; Koo KC
Sci Rep; 2019 Aug; 9(1):11899. PubMed ID: 31417160
[TBL] [Abstract][Full Text] [Related]
17. A Single-Arm, Low-Dose, Prospective Study of
Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
[TBL] [Abstract][Full Text] [Related]
18. Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial.
Qin X; Ji D; Gu W; Han W; Luo H; Du C; Zou Q; Sun Z; He C; Zhu S; Chong T; Yao X; Wan B; Yang X; Bai A; Jin C; Zou J; Ye D
BMC Med; 2022 Mar; 20(1):84. PubMed ID: 35241087
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
Serritella AV; Shevrin D; Heath EI; Wade JL; Martinez E; Anderson A; Schonhoft J; Chu YL; Karrison T; Stadler WM; Szmulewitz RZ
Clin Cancer Res; 2022 Apr; 28(8):1549-1559. PubMed ID: 35110415
[TBL] [Abstract][Full Text] [Related]
20. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.
Metwalli AR; Rosner IL; Cullen J; Chen Y; Brand T; Brassell SA; Lesperance J; Porter C; Sterbis J; McLeod DG
Urol Oncol; 2014 Aug; 32(6):761-8. PubMed ID: 24929891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]